Solving Big Problems with Small Molecule Degraders
Time: 5:25 pm
day: Day Two PM
Details:
- To realize on the promise of this disease-agnostic technology, Kymera has taken a unique approach to target selection, where we focus on targets that are either undrugged or inadequately drugged within key signaling pathways with clear clinical validation and validation through human genetics/causal biology, and where TPD is the best or the only solution
- Our comprehensive drug discovery engine utilizes computational tools, fit-for-purpose technologies, and quantitative translational models to design potent and selective degraders and drive consistent fidelity of translation of safety, PK/PD, and early efficacy from preclinical models to patients
- Preclinical and early clinical findings across our immunology and oncology pipeline support a clear degrader advantage and our differentiated strategies to advance a new generation of medicines
